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Introduction {#sec005}
============

Asthma is a common chronic inflammatory disease that affects more than 300 million people worldwide, and imposes a high disease burden and economic impact globally \[[@pone.0166833.ref001]--[@pone.0166833.ref003]\]. Despite taking high-dosage inhaled corticosteroids according to the Global Initiative for Asthma (GINA) guidelines, at least 40% of patients continue to suffer from inadequately controlled symptoms, either because they are truly resistant or because they do not take them \[[@pone.0166833.ref004], [@pone.0166833.ref005]\]. Patients who remain uncontrolled can use other drugs such as leukotriene-receptor antagonists, slow-release theophylline, and long-acting anticholinergics \[[@pone.0166833.ref006]\]. Since the anti-immunoglobulin (Ig)E humanized monoclonal antibody omalizumab became the first biological treatment approved for treating allergic asthma, many small molecules and monoclonal antibodies targeting biomolecular specificities have been investigated for treating symptomatic asthma \[[@pone.0166833.ref007]\]. Eosinophilic inflammatory infiltration is a central event in asthma pathogenesis. IL-5 is the chief cytokine responsible for eosinophil production, survival, maturation and recruitment and activation at allergic inflammation sites \[[@pone.0166833.ref008]\]. Preclinical studies have demonstrated a key role for IL-5 in murine models of allergen-induced airway eosinophilia and hyperresponsiveness \[[@pone.0166833.ref009]\]. Given the relationship of IL-5 to eosinophilia and asthma severity, human(ized) monoclonal antibodies targeting IL-5 have shown great promise in severe refractory asthma with persistent eosinophilia \[[@pone.0166833.ref010], [@pone.0166833.ref011]\]. The anti-IL-5 agents benralizumab, reslizumab, and mepolizumab have been investigated for treating asthma \[[@pone.0166833.ref012], [@pone.0166833.ref013]\]. However, their effects on lung function (especially FEV~1~) have been less consistent. Here, we conducted a meta-analysis of randomized, controlled trials (RCTs) to assess whether anti-IL-5 monoclonal antibodies therapy is safe and effective in patients (more than 12 years) with asthma.

Methods {#sec006}
=======

Literature searches and study selection {#sec007}
---------------------------------------

PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles published from 1946 to October 2016, using the search terms: ''anti--interleukin-5" or ''mepolizumab" or "benralizumab" or "reslizumab" or "monoclonal antibody" or "anti-IL-5", combined with ''asthma". Language restrictions were not applied. Reviews and the reference lists of relevant articles were also screened for additional articles of interest. Two independent authors (FPW and TL) screened all references according to the selection criteria. To ensure a complete review of the available studies, the abstracts of relevant scientific meetings were also examined, but trials published solely in abstract form were excluded. Any disagreements were resolved by consensus with a third author when necessary. The details of the search strategy are displayed in [S1 Table](#pone.0166833.s001){ref-type="supplementary-material"}.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Eligible clinical trials were defined as: (1) adults/adolescents (≥12 years) with diagnosis of asthma; (2) investigations of patients who received anti-interleukin-5 monoclonal antibody therapy at any dose, placebo-controlled or standard therapy; (3) randomized (parallel group) placebo-controlled trials, and (4) RCTs reporting the following outcomes: blood and sputum eosinophil count, asthma exacerbation, lung function, asthma control and quality of life scores, rescue use of SABA and adverse events. We excluded non-randomized, observational, cohort, case-control and non-blinded clinical trials. FPW and TL independently screened all references according to the selection criteria. Differences in opinion about inclusion were resolved by mutual agreement and arbitration of a third author (HM).

Data extraction and quality assessment {#sec009}
--------------------------------------

FPW and TL independently extracted related data in blinded fashion from eligible studies based on the predefined criteria, which included the characteristics of the trials, interventions, and outcomes. The predefined primary outcomes were lung function \[first second forced expiratory volume (FEV~1~), FEV~1~% of predicted value, peak expiratory flow (PEF), histamine PC~20~\], the Asthma Quality of Life Questionnaire (AQLQ) scores, and asthma exacerbation. Asthma exacerbation was defined as a worsening of asthma requiring increased corticosteroids or albuterol dose to control symptoms and/or the need for asthma-related emergency treatment/hospitalization. Secondary outcomes were adverse events and efficacy outcomes \[blood eosinophil count, sputum eosinophils (%), short-acting β-agonist (SABA) rescue use\]. The risk of bias was assessed using Cochrane-recommended tools, which included: (1) adequate sequence generation; (2) allocation concealment; (3) blinding; (4) incomplete outcome data addressed; (5) free of selective reporting; and (6) free of other bias \[[@pone.0166833.ref014]\].

Statistical analyses {#sec010}
--------------------

All analyses were performed with Review Manager (Version 5.3, The Cochrane Collaboration) and Stata (Version 12.0, Stata Corporation, USA), *P* \<0.05 was considered statistically significant. If a study presented more than two interventions, we combined two or three intervention groups into a single intervention group in accordance with the Cochrane handbook.^9^ Random-effects model was applied in all data analyses regardless of statistical heterogeneity. Risk ratio (RR) and 95% CIs were used to analyze dichotomous data, and mean difference and 95% CI were used for continuous data. Heterogeneity assumptions were assessed using the *I*^*2*^ statistic (*I*^*2*^\>50% indicates significant heterogeneity), and tested with the χ^2^ statistic (*P*\<0.05). However, the number of studies affects both the power of the heterogeneity test and the heterogeneity measures *I*^*2*^, but not $H_{M}^{2}$ \[[@pone.0166833.ref015]\]. In order to the increase the power of detecting heterogeneity, the 95% CI of *I*^*2*^ and $H_{M}^{2}$ were calculated \[[@pone.0166833.ref015]--[@pone.0166833.ref017]\]. If substantial heterogeneity was identified, subgroup and sensitivity analyses were performed. Moreover, we separately performed subanalyses in different drugs for each outcome. Publication bias was determined using the Begg's funnel plot and assessed by Egger's test if the number of the studies was larger than ten.

Results {#sec011}
=======

Study characteristics {#sec012}
---------------------

We identified 3047 manuscripts: 2019 from PubMed, 893 from Embase, 135 from CENTRAL. Based on title/abstract and full-text screening, 20 RCTs were included in the meta-analysis. [Fig 1](#pone.0166833.g001){ref-type="fig"} summarized the study selection process \[[@pone.0166833.ref018]--[@pone.0166833.ref037]\].

![Flow chart of study identification, inclusion, and exclusion.](pone.0166833.g001){#pone.0166833.g001}

Tables [1](#pone.0166833.t001){ref-type="table"}--[3](#pone.0166833.t003){ref-type="table"} lists the RCT characteristics, and [Table 4](#pone.0166833.t004){ref-type="table"} describes the baseline characteristics of the patients enrolled. Sample sizes ranged from 19 to 1306 subjects. Nine, five, and six trials used mepolizumab \[[@pone.0166833.ref018]--[@pone.0166833.ref026]\], reslizumab \[[@pone.0166833.ref027]--[@pone.0166833.ref031]\], and benralizumab \[[@pone.0166833.ref032]--[@pone.0166833.ref037]\], respectively. Treatment duration ranged from 1 day to 56 weeks and follow-up ranged from 12 to 56 weeks. Seven studies administered drugs used subcutaneous injection \[[@pone.0166833.ref025], [@pone.0166833.ref026], [@pone.0166833.ref032], [@pone.0166833.ref033], [@pone.0166833.ref035]--[@pone.0166833.ref037]\], while the remaining studies used intravenous infusion \[[@pone.0166833.ref018]--[@pone.0166833.ref024], [@pone.0166833.ref027]--[@pone.0166833.ref031], [@pone.0166833.ref034]\]. Nine studies involved patients with severe/refractory asthma \[[@pone.0166833.ref022]--[@pone.0166833.ref028], [@pone.0166833.ref036], [@pone.0166833.ref037]\]; four studies included patients with mild, mild to moderate, or moderate asthma \[[@pone.0166833.ref018]--[@pone.0166833.ref021]\]; the remaining studies did not specify asthma severity \[[@pone.0166833.ref029]--[@pone.0166833.ref035]\]. Corren et al. \[[@pone.0166833.ref030]\] and Castro et al. \[[@pone.0166833.ref033]\] studied patients with non-eosinophilic asthma.

10.1371/journal.pone.0166833.t001

###### Characteristic of randomized controlled trials included.

![](pone.0166833.t001){#pone.0166833.t001g}

  Reference                                  Study Design                           No. of Subjects   Population                                                 Age      drug          dosing                                                                              Outcomes                                                                                              Follow-up   Exacerbation definition
  ------------------------------------------ -------------------------------------- ----------------- ---------------------------------------------------------- -------- ------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Leckie 2000[@pone.0166833.ref018]          multi-center, double-blind             24                mild atopic asthma                                         18--45   Mepolizumab   Single IV dose of 2.5 or 10 mg/kg or placebo for one day                            Blood and sputum eosinophils; histamine PC~20;~                                                       16 weeks    NM
  Flood-Page PT 2003[@pone.0166833.ref019]   Two-center, double-blind parallel      24                mild atopic asthma                                         18--55   Mepolizumab   Three IV doses of 750 mg or placebo for 8 weeks                                     Blood eosinophils;FEV~1~; PEFR; histamine PC~20~                                                      20 weeks    NM
  Büttner 2003[@pone.0166833.ref020]         multi-center, double-blind             19                mild or moderate asthma with ICS                           20--59   Mepolizumab   Three IV doses of 250, 750 mg or placebo for 12 weeks                               Blood eosinophils                                                                                     6 months    NM
  Flood-Page P 2007[@pone.0166833.ref021]    multi-center, double-blind             362               moderate persistent asthma with ICS                        18--55   Mepolizumab   Three IV doses of 250, 750 mg or placebo for 12 weeks                               Blood and sputum eosinophils;FEV~1~; PEF; symptom scores; asthma exacerbations                        20 weeks    An acute worsening of asthma requiring additional treatment in excess of an increase in short-acting β~2~-agonist.
  Haldar 2009[@pone.0166833.ref022]          Single-center doubleblind,paralle      61                refractory eosinophilic asthma                             18--72   Mepolizumab   Twelve IV doses of 750 mg or placebo for 50 weeks                                   Blood and sputum eosinophils;FEV~1~; AQLQ; JACQ; FENO; histamine PC~20~;asthma exacerbations          50 weeks    Periods of deterioration in asthma control in subjects who had been treated with high-dose oral prednisolone for at least 5 days
  Nair 2009[@pone.0166833.ref023]            Single-center, double-blind, paralle   20                severe asthma on OCS with persistent sputum eosinophilia   NM       Mepolizumab   Five IV doses of 750 mg or placebo for 16 weeks                                     Blood and sputum eosinophils;FEV~1~;JACQ; asthma exacerbations; reduction in the dose of prednisone   26 weeks    A patient initiated increase in the daily dose of albuterol of four or more puffs to control symptoms of chest tightness or as any one of the following: nocturnal or waking respiratory symptoms on two consecutive days, a decrease of more than 15% in the FEV~1~ from the level at randomization after the use of albuterol, or a 2-point worsening in the Likert score for cough by the investigators at their discretion on the basis of general clinical worsening.
  Pavord 2012[@pone.0166833.ref024]          multi-center, double-blind             621               severe eosinophilic asthma                                 12--74   Mepolizumab   Thirteen IV doses of 75, 250, or 750 mg or placebo for 52 weeks                     Blood and sputum eosinophils;FEV~1~; AQLQ; ACQ-6;asthma exacerbations                                 52 weeks    Worsening of asthma requiring use of oral corticosteroids for 3 or more days, admission, or a visit to the emergency department, 50% increase in rescue medication on at least 2 of 3 successive days, increased frequency of nocturnal awakening due to asthma for at least 2 of 3 successive nights, or overall asthma symptom score of five (scale one to five) for at least 2 of 3 successive days
  Bel 2014[@pone.0166833.ref025]             multi-center doubleblind, parallel     135               severe eosinophilic asthma                                 16--74   Mepolizumab   Six SC doses of 100 mg or placebo for 20 weeks                                      Asthma exacerbations; ACQ-5;SGRQ; reduction in the oral glucocorticoid dose                           32 weeks    A worsening of asthma leading to the doubling (or more) of the existing maintenance dose of oral glucocorticoids for 3 or more days or hospital admission or an emergency department visit for asthma treatment
  Ortega 2014[@pone.0166833.ref026]          multi-center double-blind,             576               severe eosinophilic asthma                                 12--84   Mepolizumab   Nine doses of 75 mg IV or 100 mg SC or placebo for 32 weeks                         Asthma exacerbations; ACQ-5;SGRQ;FEV1;blood eosinophil                                                40 weeks    Worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least 3 days or the patient visited an emergency department or was hospitalized
  Kips JC 2003[@pone.0166833.ref027]         multi-center, double-blind             32                severe persistent asthma                                   NM       Reslizumab    Single IV doses of 0.03mg/kg,0.1mg/kg, 0.3mg/kg, or 1mg/kg or placebo for one day   Blood and sputum eosinophils; FEV~1~;                                                                 90 days     NM

10.1371/journal.pone.0166833.t002

###### Characteristic of randomized controlled trials included.

![](pone.0166833.t002){#pone.0166833.t002g}

  Reference                                 Study Design                                        No. of Subjects           Population                                                      Age      drug           dosing                                                                                                                            Outcomes                                                                     Follow-up             Exacerbation definition
  ----------------------------------------- --------------------------------------------------- ------------------------- --------------------------------------------------------------- -------- -------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Castro 2011[@pone.0166833.ref028]         multi-center, double-blind                          106                       severe eosinophilic asthma                                      18--75   Reslizumab     Three IV doses of 3mg/kg or placebo for 12 weeks                                                                                  Blood and sputum eosinophils;ACQ-7; FEV~1~; asthma exacerbations             15 weeks              A 20% or more decrease from baseline in FEV~1~; or worsening of Asthma requiring emergency treatment, hospital admission, or three or more days of oral corticosteroid treatment.
  Castro 2015[@pone.0166833.ref029]         two duplicate multi-center, double-blind parallel   Study 1:489 Study 2:464   uncontrolled asthma                                             12--75   Reslizumab     Thirteen IV doses of 3mg/kg or placebo for 52 weeks                                                                               Blood eosinophils; asthma exacerbations; FEV~1~; AQLQ; ACQ-7; rescue SABAs   52 weeks              Worsening of asthma that resulted in use of systemic corticosteroids in patients not already receiving treatment, or a two-times increase in the dose of either inhaled corticosteroids or systemic corticosteroids for 3 or more days, or the need for asthma-related emergency treatment
  Corren 2016[@pone.0166833.ref030]         multi-center, double-blind                          492                       non-eosinophilic asthma                                         18--65   Reslizumab     Four IV doses of 3mg/kg or placebo for 16 weeks                                                                                   Blood eosinophils;ACQ-7; FEV~1~;rescue SABAs                                 28 weeks              NM
  Bjermer L 2016[@pone.0166833.ref031]      multi-center, double-blind parallel                 315                       uncontrolled asthma                                             12--75   Reslizumab     Four IV doses of 0.3mg/kg, 3mg/kg or placebo for 16 weeks                                                                         Blood eosinophils; FEV~1~; FVC;ACQ-6(5);FEF~25-75%~; ASUI; AQLQ              20 weeks              A reduction in FEV~1~ of ≥20%, hospitalization due to asthma, emergency treatment of asthma, or use of systemic corticosteroids for ≥3 days
  Laviolette 2013[@pone.0166833.ref032]     multi-center, double-blind                          cohort 1:13 cohort 2:14   eosinophilic asthma                                             18--65   Benralizumab   Single IV dose of 1mg/kg or placebo (cohort 1) for one day or three SC doses of 100 or 200 mg or placebo (cohort 2) for 56 days   Blood, sputum eosinophils; adverse events                                    84 days or 140 days   NM
  Castro 2014[@pone.0166833.ref033]         multi-center, double-blind                          group 1:324 group 2:282   group 1: eosinophilic asthma group 2: non-eosinophilic asthma   18--75   Benralizumab   Eight SC doses of 2, 20, or 100 mg for eosinophilic patients and 100 mg for non-eosinophilic or placebo for 1 year                Blood eosinophils; asthma exacerbations; FEV~1~; AQLQ;                       1 year                An increase in asthma symptoms that did not resolve after rescue medication and needed treatment with systemic steroids for at least 3 days
  Nowak 2015[@pone.0166833.ref034]          multi-center double-blind, parallel                 110                       acute asthma                                                    18--60   Benralizumab   Single IV dose of 0.3mg/kg or 1mg/kg or placebo for one day                                                                       Blood eosinophils; asthma exacerbations; FEV~1~; ACQ-7; AQLQ                 168 days              An increase of asthma symptoms that did not resolve within 2 hours after the use of rescue albuterol or corticosteroids and required an unscheduled medical visit; or during a scheduled study visit, the subject had acute asthma symptoms and a reduction of greater than or equal to 20% in predicted peak expiratory flow or FEV~1~, which in the opinion of the investigator required treatment.
  Park HS 2016[@pone.0166833.ref035]        multi-center, double-blind                          106                       eosinophilic asthma                                             20--75   Benralizumab   Seven SC doses of 2, 20, or 100 mg or placebo for 40 weeks                                                                        Blood eosinophils; asthma exacerbations; FEV1; PEF; ACQ-6;FENO               52 weeks              An increase in asthma symptoms that required treatment with systemic steroids for at least 3 days.
  Bleecker E R 2016[@pone.0166833.ref036]   multi-center, double-blind parallel                 1306                      severe uncontrolledasthma with eosinophilia                     12--75   Benralizumab   Twelve SC doses of 30 mg or Seven SC doses of 30mg or placebo for 48 weeks                                                        Asthma exacerbations; FEV1; ACQ-6; AQLQ                                      48 weeks              A worsening of asthma that led to one of the following: (1) use of systemic corticosteroids, or temporary increase in a stable oral corticosteroid background dosage, for at least 3 days or a single injectable dose of corticosteroids; (2) emergency department or visit to an urgent care centre (\<24 h) because of asthma that needed systemic corticosteroids;or (3) inpatient hospital stay (≥24 h) because of asthma

10.1371/journal.pone.0166833.t003

###### Characteristic of randomized controlled trials included.

![](pone.0166833.t003){#pone.0166833.t003g}

  Reference                                   Study Design                          No. of Subjects   Population                                 Age      drug           dosing                                                                        Outcomes                                  Follow-up   Exacerbation definition
  ------------------------------------------- ------------------------------------- ----------------- ------------------------------------------ -------- -------------- ----------------------------------------------------------------------------- ----------------------------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FitzGerald J M 2016[@pone.0166833.ref037]   multi-center, double-blind parallel   1205              severe,uncontrolled, eosinophilic asthma   12--75   Benralizumab   Fourteen SC doses of 30mg or Eight SC doses of 30mg or placebo for 56 weeks   Asthma exacerbations; FEV1; ACQ-6; AQLQ   56 weeks    An asthma exacerbation was defined as a worsening of asthma that led to one of the following: (1) use of systemic corticosteroids for 3 days or more or a temporary increase in a stable, background dosage of oral corticosteroids; (2) an emergency department or urgent care visit (\<24 h) due to asthma that required systemic corticosteroids; or (3) an inpatient admission to hospital (≥24 h) due to asthma.

FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; histamine PC20, provocative concentration of histamine required to cause a 20% fall in FEV1; JACQ, Juniper Asthma Control Questionnaire; AQLQ, the Asthma Quality of Life Questionnaire; ACQ, Asthma Control Questionnaire; FeNO, fraction of exhaled nitric oxide; SABAs: short-acting beta-agonists (SABAs); SC: subcutaneous injections; IV, intravenous; ICS, inhaled corticosteroid; OCS, oral corticosteroid; NM: not mentioned

10.1371/journal.pone.0166833.t004

###### Baseline Characteristics of Patients in the 20 Studies Included.

![](pone.0166833.t004){#pone.0166833.t004g}

  Refs.                                       No. [\*](#t004fn001){ref-type="table-fn"}   Sex                                  Age                                           Blood Eosinophils                                      FEV~1~% Predicted                             Diagnosis of asthma                       PEF
  ------------------------------------------- ------------------------------------------- ------------------------------------ --------------------------------------------- ------------------------------------------------------ --------------------------------------------- ----------------------------------------- --------------
  Leckie 2000[@pone.0166833.ref018]           16                                          NM                                   29 (6.29)                                     0.25 (0.1)                                             86.15 (9.58)                                  NM                                        NM
  Flood-Page PT 2003[@pone.0166833.ref019]    11                                          9 (82)                               31 (5.5)                                      0.27 (0.18)                                            87.0 (6.3)                                    NM                                        433 (37.8)
  Büttner 2003[@pone.0166833.ref020]          12                                          5 (42)                               44.25 (10.85)                                 NM                                                     65.68 (10.48)                                 11.75 (9.27)                              NM
  Flood-Page P 2007[@pone.0166833.ref021]     236                                         112 (47)                             36 (29.4)                                     0.35 (0.25)                                            68.35 (9.2)                                   NM                                        366.6 (90.0)
  Haldar 2009[@pone.0166833.ref022]           29                                          14 (48)                              48 (7)                                        0.32 (0.38)[^&^](#t004fn003){ref-type="table-fn"}      78.1 (20.9)                                   NM                                        NM
  Nair 2009[@pone.0166833.ref023]             9                                           4 (44)                               56.4 (10.9)                                   0.68 (0.52)                                            66.6 (18.3)                                   NM                                        NM
  Pavord 2012[@pone.0166833.ref024]           461                                         171 (37)                             49.4 (11.2)                                   0.24 (1.03)[^\#^](#t004fn002){ref-type="table-fn"}     60.0 (16.3)                                   19.5 (14.4)                               NM
  Bel 2014[@pone.0166833.ref025]              69                                          25 (36)                              50 (9.7)                                      0.25 (1.245)[^\#^](#t004fn002){ref-type="table-fn"}    59.6 (17.0)                                   17.4 (11.8)                               NM
  Ortega 2014[@pone.0166833.ref026]           385                                         163 (42)                             50.5 (11.5)                                   0.285 (1.018)[^\#^](#t004fn002){ref-type="table-fn"}   60.3 (17.9)                                   20.2 (13.4)                               262 (110)
  Kips JC 2003[@pone.0166833.ref027]          18                                          12 (67)                              43 (5.9)                                      0.26 (0.04)                                            53.4 (7.6)                                    NM                                        NM
  Castro 2011[@pone.0166833.ref028]           53                                          19 (36)                              44.9 (13.94)                                  NM                                                     66.0 (15.16)                                  23.3 (11.38)                              NM
  Castro 2015[@pone.0166833.ref029]           Study 1: 245 Study 2: 232                   Study 1: 103 (42) Study 2: 88 (38)   Study 1: 48 (14.1) Study 2: 48 (14.4)         Study 1:0.696 (0.768) Study 2: 0.61 (0.412)            Study 1:63.6 (18.6) Study 2:70.4 (21.0)       Study 1:19.7 (15.2) Study 2:18.2 (14.4)   NM
  Corren 2016[@pone.0166833.ref030]           398                                         137 (34)                             44.9                                          0.281 (0.264)                                          66.8                                          26.2                                      NM
  Bjermer L 2016[@pone.0166833.ref031]        210                                         85 (40)                              43.7                                          0.65 (0.006)                                           69.6                                          20.2                                      NM
  Laviolette 2013[@pone.0166833.ref032]       cohort 1: 8 cohort 2: 9                     cohort 1: 6 (25) cohort 2: 5 (56)    cohort 1: 38.9 (14.7) cohort 2: 38.9 (13.8)   NM                                                     cohort 1: 70.5 (15.6) cohort 2: 68.7 (11.4)   NM                                        NM
  Castro 2014[@pone.0166833.ref033]           group 1: 244 group 2: 140                   group 1: 78 (32) group 2: 42 (30)    group 1: 47.2 (12.9) group 2: 50.0 (11.5)     group 1: 0.54 (0.32) group 2: 0.19 (0.12)              group 1: 65.3 (15.3) group 2: 66.8 (15.1)     NM                                        NM
  Nowak 2015[@pone.0166833.ref034]            72                                          25 (35)                              36.3 (6.8)                                    0.213 (0.393)                                          58.1                                          NM                                        NM
  Park HS 2016[@pone.0166833.ref035]          77                                          29 (38)                              53.4 (11.5)                                   0.72 (0.87)                                            67.8 (14.4)                                   NM                                        NM
  Bleecker E R 2016[@pone.0166833.ref036]     797                                         270(34)                              48.9(14)                                      0.34(0.52)                                             56.8(14.4)                                    14.9                                      NM
  FitzGerald J M 2016[@pone.0166833.ref037]   866                                         323(37)                              49.5(14)                                      0.39(0.42)                                             58.4(14.9)                                    16.3                                      NM

\*Data on all patients who received anti-interleukin 5, and all data are n (%) or mean (SD), unless otherwise stated.

^\#^Geometric mean on loge scale.

^&^geometric means±log10 SD.

NM: Not Mentioned

Primary outcomes {#sec013}
----------------

### Lung function {#sec014}

***FEV***~***1***~. Fourteen studies assessed FEV~1~ responsiveness to anti-interleukin 5 treatment \[[@pone.0166833.ref019],[@pone.0166833.ref021]--[@pone.0166833.ref024],[@pone.0166833.ref026],[@pone.0166833.ref028]--[@pone.0166833.ref031],[@pone.0166833.ref033],[@pone.0166833.ref034],[@pone.0166833.ref036],[@pone.0166833.ref037]\]. Six studies reported significant improvements in FEV1 between mepolizumab, reslizumab, and benralizumab treatments and placebo, while the remaining studies reported no effect on FEV1. [Fig 2](#pone.0166833.g002){ref-type="fig"} showed that reslizumab was more effective than other two anti-interleukin 5 monoclonal antibodies in improving FEV~1~ (MD = 0.12, 95% CI: 0.04--0.19, *P* = 0.002), and the pooled data analysis revealed a slight improvement (MD = 0.09, 95% CI: 0.06--0.12, *P*\<0.001). There was minimal heterogeneity (*I*^*2*^ = 10%, *P* = 0.34, 95% CI -53% to 47%, $H_{M}^{2} = 0.10$).

![The effect of anti-interleukin 5 versus placebo on FEV~1~.\
CI = confidence interval; FEV~1~ = forced expiratory volume in 1 second; SD = standard derivation; IV = Inverse Variance.](pone.0166833.g002){#pone.0166833.g002}

### FEV~1~% of predicted value {#sec015}

Seven trials using three different anti-interleukin 5 antibodies reported FEV~1~% of predicted value \[[@pone.0166833.ref023],[@pone.0166833.ref025]--[@pone.0166833.ref028],[@pone.0166833.ref034],[@pone.0166833.ref035]\]. Overall, anti-interleukin 5 treatment was associated with modestly improved in FEV~1~% of predicted value compared to placebo (MD = 3.75, 95% CI 1.66--5.83, *P* = 0.0004) ([Fig 3](#pone.0166833.g003){ref-type="fig"}), and heterogeneity was not statistically significant (*I*^*2*^ = 19%, P = 0.29, 95% CI 0% to 62%, $H_{M}^{2} = 0.23$). When looking at subgroups, there were no differences by benralizumab (MD = -0.88, 95% CI -6.88--5.13, *P* = 0.78).

![The effect of anti-interleukin 5 versus placebo on FEV~1~% of predicted value.](pone.0166833.g003){#pone.0166833.g003}

### Peak expiratory flow (PEF) and Provocative concentration of histamine (histamine PC~20~) {#sec016}

Four trials depicted PEF change after anti-interleukin 5 treatment \[[@pone.0166833.ref019],[@pone.0166833.ref021],[@pone.0166833.ref034],[@pone.0166833.ref035]\], and only three about mepolizumab studies reported the results in histamine PC~20~ \[[@pone.0166833.ref018],[@pone.0166833.ref019],[@pone.0166833.ref022]\]. Results from the pooled data illustrated that anti-interleukin 5 could not significantly improve PEF (MD = 5.45, 95% CI: -2.83--13.72, *P* = 0.2) ([Fig 4](#pone.0166833.g004){ref-type="fig"}) or PC~20~ (MD = -0.62, 95% CI: -1.92--0.68, *P* = 0.35) ([Fig 5](#pone.0166833.g005){ref-type="fig"}). Studies were highly homogeneous (*I*^*2*^ = 0%, *P* = 0.73, 95% CI 0% to 84%, $H_{M}^{2} = 0$; *I*^*2*^ = 0%, *P* = 0.73, 95% CI 0% to 89%, $H_{M}^{2} = 0$). Our confidence in these results is low due to the wide CI.

![The effects of anti--interleukin-5 on PEF (L/min).](pone.0166833.g004){#pone.0166833.g004}

![The effects of anti--interleukin-5 on histamine PC~20~ (mg/ml).](pone.0166833.g005){#pone.0166833.g005}

### Asthma Quality of Life Questionnaire (AQLQ) score {#sec017}

Eight trials of three different anti-interleukin 5 antibodies reported AQLQ scores \[[@pone.0166833.ref022],[@pone.0166833.ref024],[@pone.0166833.ref029],[@pone.0166833.ref031],[@pone.0166833.ref033],[@pone.0166833.ref034],[@pone.0166833.ref036],[@pone.0166833.ref037]\]. Pooled analysis showed that anti-interleukin 5 treatment was associated with significantly improved AQLQ score (MD = 0.22, 95% CI 0.15--0.30, *P*\<0.001), with no significant heterogeneity (*I*^*2*^ = 0%, *P* = 0.94, 95% CI 0% to 29%, $H_{M}^{2} = - 0.64$) ([Fig 6](#pone.0166833.g006){ref-type="fig"}). Among subgroups, AQLQ scores improved only in the trials involving reslizumab and benralizumab treatment trials (MD = 0.27, 95% CI 0.13--0.42, *P* = 0.0002; MD = 0.21, 95% CI 0.11--0.31, *P*\<0.001), but not mepolizumab (*P* = 0.08).

![The effects of anti-interleukin 5 on Asthma Quality of Life Questionnaire (AQLQ).](pone.0166833.g006){#pone.0166833.g006}

### Asthma exacerbations {#sec018}

Thirteen studies (6,072 participants) reported on asthma exacerbations \[[@pone.0166833.ref021]--[@pone.0166833.ref029],[@pone.0166833.ref033],[@pone.0166833.ref034],[@pone.0166833.ref036],[@pone.0166833.ref037]\]. [Table 1](#pone.0166833.t001){ref-type="table"} summarizes their definitions for asthma exacerbation. Although these definitions varied, all 13 studies defined exacerbation based on increased corticosteroids or albuterol dose to control symptoms and/or the need for asthma-related emergency treatment/hospitalization. [Fig 7](#pone.0166833.g007){ref-type="fig"} showed that anti-interleukin 5 monoclonal therapies were associated with a significant reduction in asthmatic exacerbation compared with placebo (RR = 0.66, 95% CI, 0.59--0.73, *P*\<0.001), but the reporting was significantly heterogeneous (*I*^*2*^ = 51%, *P*\<0.001, 95% CI 12% to 73%, $H_{M}^{2} = 1.05$).

![The effect of anti-interleukin 5 versus placebo on exacerbation.\
IV = Inverse Variance.](pone.0166833.g007){#pone.0166833.g007}

Secondary outcomes {#sec019}
------------------

### Blood and sputum eosinophils {#sec020}

18 trials included blood eosinophil analysis and six trials compared sputum eosinophil levels between anti-interleukin 5 treatment and placebo \[[@pone.0166833.ref018],[@pone.0166833.ref022]--[@pone.0166833.ref024],[@pone.0166833.ref028],[@pone.0166833.ref032]\]. As the data were reported inconsistently (data were shown as median \[range\], mean \[SD\] or geometric mean \[log10 SE\]), we did not obtain a synthesized analysis of the outcomes. However, from all the results reported, a similar outcome was identified that anti-interleukin 5 significantly decreased blood and sputum eosinophils compared with placebo ([S2 Table](#pone.0166833.s002){ref-type="supplementary-material"}).

### SABA rescue use {#sec021}

Four trials evaluated the effect of anti-interleukin 5 antibodies on SABA use ([Fig 8](#pone.0166833.g008){ref-type="fig"}) \[[@pone.0166833.ref021],[@pone.0166833.ref029]--[@pone.0166833.ref031]\]. Analyses of these studies showed a non-significant decrease in the anti--interleukin 5 group compared with the placebo group (MD = -0.11, 95% CI -0.3--0.07, *P* = 0.22), with low heterogeneity (*I*^*2*^ = 11%, *P* = 0.34, 95% CI 0% to 54%, $H_{M}^{2} = 0.13$) among the studies.

![The effects of anti-interleukin-5 on SABA rescue use.](pone.0166833.g008){#pone.0166833.g008}

### Adverse events {#sec022}

13 studies reported adverse events, and anti-interleukin 5 therapy was well tolerated \[[@pone.0166833.ref023]--[@pone.0166833.ref026],[@pone.0166833.ref028]--[@pone.0166833.ref033],[@pone.0166833.ref035]--[@pone.0166833.ref037]\]. The pooled RR was 0.93 (95% CI: 0.89--0.98), which showed the lower adverse events incidence were slightly in the anti-interleukin 5 group (*P* = 0.002), with modest heterogeneity (*I*^*2*^ = 46%, *P* = 0.02, 95% CI 2.3% to 71%, $H_{M}^{2} = 0.87$) ([Fig 9](#pone.0166833.g009){ref-type="fig"}). However, sensitivity analysis that excluded two studies which included patients with non-eosinophilic asthma revealed no heterogeneity (*I*^*2*^ = 0%, *P* = 0.75, 95% CI 0% to 48%, $H_{M}^{2} = - 0.3$) \[[@pone.0166833.ref030],[@pone.0166833.ref033]\]. Therefore, the heterogeneity can be explained by the varied participant types. In subgroup analysis, however, only treatment with reslizumab was associated with a trend of lower adverse events incidence (RR = 0.88, 95% CI: 0.81--0.96, *P* = 0.003), while no significant differences were found in both mepolizumab (RR = 0.95, 95% CI: 0.89--1.01, *P* = 0.12) and benralizumab treatment groups (RR = 0.98, 95% CI: 0.92--1.04 *P* = 0.44).

![The effect of anti-interleukin 5 versus placebo on adverse events.](pone.0166833.g009){#pone.0166833.g009}

Risk of bias {#sec023}
------------

[Fig 10](#pone.0166833.g010){ref-type="fig"} summarizes the methodological domain assessments for each included study. Most trials had low risk of bias across the six domains. The allocation sequence was adequately generated and concealed in fourteen trials, \[[@pone.0166833.ref022]--[@pone.0166833.ref029],[@pone.0166833.ref032]--[@pone.0166833.ref037]\]. The randomization techniques included computer generated randomization codes and minimization. The remaining trials did not report the method used, and we were unable to obtain this information. All but one study was described as double-blinded \[[@pone.0166833.ref020]\]. Almost all RCTs reported complete outcome data, only one trial reported on attrition insufficiently \[[@pone.0166833.ref027]\].

![Risk of bias summary.](pone.0166833.g010){#pone.0166833.g010}

Subgroup analyses and sensitivity analysis {#sec024}
------------------------------------------

To clarify the heterogeneity or identify the optimal patients for this treatment, subgroup analyses were carried out for asthma exacerbations and FEV~1~ ([Table 5](#pone.0166833.t005){ref-type="table"}). The studies were stratified according to effects model, asthma severity, asthma types, sample size, drug administration dosage, follow-up duration and published year. Subgroup analyses showed the efficacy of anti-interleukin 5 on asthma exacerbations were only influenced by asthma severity. Most subgroups showed significantly reduced exacerbations risk. Single dose anti-interleukin 5 in two studies showed no significant differences in exacerbation rates. However, the subgroup results should be interpreted with caution because of the limited sample size and potential bias inherent to subgroup analysis. The meta-analysis findings remained stable with multicenter trials. In addition, excluding the results of any single study did not alter the overall findings. Furthermore, based on the subgroups analysis, we could know that anti-interleukin 5 can significantly improve the FEV~1~ of severe asthma (MD = 0.11, *P*\<0.001) and eosinophilic asthma (MD = 0.11, *P* = 0.001). This further confirmed that the severe eosinophilic asthma patients are the optimal patients for anti-interleukin 5 treatment.

10.1371/journal.pone.0166833.t005

###### Subgroup analysis and sensitivity analyses of asthma exacerbation and FEV~1~ in RCTs.

![](pone.0166833.t005){#pone.0166833.t005g}

  Stratification             asthma exacerbation                            FEV~1~                                                                                                                                               
  -------------------------- ---------------------------------------------- ------------------ --------------------------------------------- ----- ---------------------------------------------- -------------------- --------- -----
  **Subgroup analysis**                                                                                                                                                                                                          
  **Effects model**                                                                                                                                                                                                              
   random-effects model      6072(13)                                       0.66(0.59--0.73)   \<0.001                                       51    6725(14)                                       0.09(0.06--0.12)     \<0.001   10
   fixed effects model       6072(13)                                       0.63(0.59--0.67)   \<0.001                                       51    6725(14)                                       0.09(0.06--0.12)     \<0.001   10
  **Asthma severity**                                                                                                                                                                                                            
   mild or moderate asthma   362(1)                                         0.85(0.51--1.43)   0.55                                          ...   365(2)                                         -0.02(-0.2--0.15)    0.8       0
   severe asthma             4090(8)                                        0.59(0.53--0.65)   \<0.001                                       23    3901(7)                                        0.11(0.07--0.14)     \<0.001   35
   mixed asthma              1620(4)                                        0.73(0.65--0.82)   \<0.001                                       18    2459(5)                                        0.08(0.04--0.12)     \<0.001   0
  **Asthma types**                                                                                                                                                                                                               
   eosinophilic asthma       3117(7)[\*](#t005fn001){ref-type="table-fn"}   0.64(0.56--0.74)   \<0.001                                       65    3002(6)[\*](#t005fn001){ref-type="table-fn"}   0.11(0.05--0.17)     \<0.001   46
   mon-eosinophilic asthma   282(1)                                         0.76(0.60--0.97)   0.02                                          ...   773(2)                                         0.06(0.00--0.11)     0.05      0
   mixed asthma              2673(6)                                        0.66(0.57--0.77)   \<0.001                                       24    2950(7)                                        0.10(0.05--0.15)     \<0.001   0
  **No. of subjects**                                                                                                                                                                                                            
   \<100                     107(3)                                         0.63(0.28--1.45)   0.28                                          46    99(3)                                          -0.04(-0.23--0.15)   0.68      0
   ≥100                      5965(10)                                       0.65(0.59--0.72)   \<0.001                                       51    6626(11)                                       0.09(0.06--0.13)     \<0.001   16
  **Follow-up**                                                                                                                                                                                                                  
   \<50 weeks                2530(8)                                        0.64(0.54--0.76)   \<0.001                                       33    3168(9)                                        0.10(0.05--0.16)     \<0.001   34
   ≥50 weeks                 3542(5)                                        0.67(0.59--0.76)   \<0.001                                       67    3557(5)                                        0.08(0.04--0.12)     \<0.001   0
  **Intervention dosage**                                                                                                                                                                                                        
   single dose               134(2)                                         0.93(0.61--1.42)   0.73                                          0     103(1)                                         -0.11(-0.39--0.17)   0.45      ...
   multiple doses            5938(11)                                       0.65(0.57--0.74)   \<0.001                                       58    6622(13)                                       0.09(0.07--0.12)     \<0.001   5
  **Year**                                                                                                                                                                                                                       
   published year ≤2011      575(5)                                         0.73(0.52--1.02)   0.07                                          21    544(5)                                         0.08(-0.01--0.25)    0.4       54
   published year \>2011     5497(8)                                        0.64(0.58--0.71)   \<0.001                                       56    6181(9)                                        0.09(0.06--0.12)     \<0.001   0
  **Sensitivity analysis**                                                                                                                                                                                                       
   Non-multicenter           5991(11)                                       0.65(0.59--0.72)   \<0.001                                       47    6626(11)                                       0.09(0.06--0.13)     \<0.001   16
   One-study-out method      ...                                            ...                From 0.65 (0.58--0.71) to 0.68 (0.61--0.75)   ...                                                  ...                            

\*The Castro 2015 inclued two groups, group 1 for eosinophilic asthma, group 2 for non-eosinophilic asthma.

Publication bias {#sec025}
----------------

Publication bias was assessed using Begg's funnel plot and Egger's test. Begg's funnel plot of the 14 studies evaluated the effect of anti-interleukin 5 on FEV1 and the Egger's test suggested no publication bias (*P* = 0.78, [Fig 11](#pone.0166833.g011){ref-type="fig"}). And also no publication bias was detected by Egger's test for other outcomes analysis (all *P*\>0.05). However, we could not fully exclude publication bias in four outcomes (FEV~1~%, PEF, histamine PC20, SABA rescue use); we could not evaluate the potential risk of publication bias, since these tests have very low power in meta-analysis.

![Begg's funnel plot evaluated the effect of anti-interleukin-5 on FEV~1~.](pone.0166833.g011){#pone.0166833.g011}

Discussion {#sec026}
==========

We identified 20 RCTs investigating the effect of anti-interleukin 5 monoclonal antibodies in patients with asthma. The results suggest that anti-interleukin 5 therapy was well tolerated and could significantly improve AQLQ score, FEV~1~, FEV~1~% of predicted value, and decrease asthmatic exacerbation, blood and sputum eosinophil levels, but yielded no effects in PEF, PC~20~, SABA rescue use. Additionally, reslizumab seems to be safer and more effective than the other two drugs based on all outcomes. However, since varied baseline of patients among studies, it is not possible to draw a firm conclusion. Different from previous systematic reviews that only included studies of on mepolizumab \[[@pone.0166833.ref038], [@pone.0166833.ref039]\], we included trials about mepolizumab and other two anti-interleukin-5 antibodies-reslizumab and benralizumab. Additionally, the results should be interpreted with caution due to with the relatively small sample sizes and small number of included trials. Therefore, our results may be more believable. In contrast to previous systematic reviews, we found that anti-interleukin-5 treatment slightly increased FEV~1~ and FEV~1~% of predicted value. But the clinical relevance of this finding to patients may not be clinically important because of the modest improvement. Only three or four studies reported detailed data, therefore we could not draw exact conclusions for these two parameters due to the insufficient data. Previous two systematic reviews failed to show a significant effect in FEV~1~, likely due to small number of trials analyzed \[[@pone.0166833.ref038], [@pone.0166833.ref039]\]. Liu et al \[[@pone.0166833.ref039]\] converted and pooled continuous variable data such as blood and sputum eosinophils. To reduce the possible bias resulting from data conversion, we only obtained qualitative descriptions with estimations of the two outcomes. Besides, when studies with multiple intervention groups, Liu et al \[[@pone.0166833.ref039]\] only selected one pair of interventions and exclude the others which are not generally recommended by Cochrane handbook. Our meta-analysis found that there was a significant improvement in AQLQ score, which is consistent with previous two meta-analyses. However, as the mean change in AQLQ score is less than the clinical minimally important difference of 0.5 units, the clinical relevance of this finding may not be clinically important to patients \[[@pone.0166833.ref040]\]. Asthma exacerbations are associated with substantial morbidity and mortality \[[@pone.0166833.ref041]\]. Decreasing the asthma exacerbations rate is a key goal in asthma management. Our meta-analysis showed a significant reduction in exacerbation rates. The clinical relevance of this finding to patients may be clinically important. The inconsistency of the results between asthma exacerbations and rescue use of SABA might due to the next two reasons: 1) the slight improvement in lung functions; 2) most exacerbations in trials were predominantly those that would generally be judged severe on the basis of a need for systemic corticosteroid or requiring admission or visit to emergency. This systematic review also has limitations. First, we aimed to identify the overall effect of anti-interleukin-5 therapy on asthma, the asthma severity and baseline asthma therapy varied among studies ([Table 2](#pone.0166833.t002){ref-type="table"}), so the population examined in this review was too heterogeneous to draw any conclusions about the general asthma population. Further research is needed to clarify which subgroups of patients with asthma can benefit from this treatment. Second, in accordance with the Cochrane handbook, we combined two or three intervention groups into a single intervention group regardless of different intervention dosage and administration routine. This made identifying the optimal dose and regimen for treating asthma difficult. Thirdly, although these studies shared many common issues, there were also substantial subgroup and study heterogeneities. Moreover, there also was significant heterogeneity among studies evaluating asthma exacerbation and adverse events; although we used a random-effects model to account for this, the correction is only partial. As for PEF, histamine PC20 and SABA rescue use, given the small number of studies being meta-analysed, it is difficult to detect heterogeneity and accurately estimate it \[[@pone.0166833.ref042]\]. Lastly, Ortega et al \[[@pone.0166833.ref043]\] re-examined baseline blood eosinophil counts from previous two studies \[[@pone.0166833.ref024],[@pone.0166833.ref026]\] on mepolizumab, they found that the use of the baseline at a threshold of at least 150 cells/μL can be a reliable and simple biomarker for patient selection associated with positive clinical responses to mepolizumab treatment. However, due to the lack of individual patient data among all studies, we failed to further analysis the relationship between blood eosinophil counts≥150 cells/μL at baseline and outcomes of mepolizumab, reslizumab and benralizumab treatment.

Conclusions {#sec027}
===========

Our study indicates that anti-interleukin-5 therapy is safe and may reduce asthma exacerbation risk, slightly improve FEV~1~, FEV~1~%, and quality of life; and decrease blood and sputum eosinophil levels, although PEF, PC~20~ were not improved or SABA rescue use reduced. Anti-interleukin-5 therapy may therefore be beneficial as adjunct asthma therapy, particularly in severe and eosinophilic asthma. Further trials are necessary to determine the most effective asthma treatment drug and studies need to be performed that distinguish which patients will respond to particular antibodies, both within and between classes (i.e., who will respond to mepolizumab vs. benralizumab or? reslizumab vs. benralizumab?).
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